Creating a new generation of small molecule protease inhibitors

2016 News Releases

Keyword Search
 
DateTitle 
11/29/16KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
Leading Plasma Kallikrein Researcher Further Strengthens Scientific Team CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Nov. 29, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the appointment of Edward P. Feener, Ph.D. as Chief Scientific Officer (CSO) of the Company. Dr. Feener is a scientific co-founder of KalVist... 
Printer Friendly Version
11/22/16KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics
—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker "KALV" — —Continued focus on development of protease inhibitors with multiple molecules for oral treatment of hereditary angioedema (HAE) in the clinic in 2017— —Appoints Benjamin L. Palleiko as Chief Financial Officer— CAMBRIDGE, Mass. and PALO ALTO, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, devel... 
Printer Friendly Version
06/15/16Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement
--Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME) --KalVista to become a wholly owned subsidiary of Carbylan, and KalVista shareholders to become majority owners of Carbylan upon the closing of the transaction PALO ALTO, Calif. and SALISBURY, United Kingdom, June 15, 2016 (GLOBE NEWSWIRE) -- Carbylan T... 
Printer Friendly Version
04/15/16Carbylan Therapeutics Announces Decision to Pursue Strategic Transaction
Carbylan to suspend clinical development of Hydros-TA, reduce headcount and preserve capital PALO ALTO, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company, announced today that it has suspended further clinical development of Hydros-TA and that it is actively pursuing a strategic transaction, including a merger or acquisition of the company. As previously announced, Carbylan has engaged Wedbush PacGrow to act as its strategic financ... 
Printer Friendly Version
03/17/16Carbylan Therapeutics Engages Wedbush PacGrow to Advise on Strategic Alternatives
PALO ALTO, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced that it has engaged Wedbush PacGrow to advise on strategic alternatives for the Company. "As we work to enhance value for our shareholders, we believe it is important to identify and evaluate all options available to us, and believe that Wedbush PacGrow is an ideal partner to advi... 
Printer Friendly Version